260 related articles for article (PubMed ID: 25813021)
1. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.
Korangath P; Teo WW; Sadik H; Han L; Mori N; Huijts CM; Wildes F; Bharti S; Zhang Z; Santa-Maria CA; Tsai H; Dang CV; Stearns V; Bhujwalla ZM; Sukumar S
Clin Cancer Res; 2015 Jul; 21(14):3263-73. PubMed ID: 25813021
[TBL] [Abstract][Full Text] [Related]
2. Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death.
Qin JZ; Xin H; Nickoloff BJ
Biochem Biophys Res Commun; 2010 Jul; 398(1):146-52. PubMed ID: 20599741
[TBL] [Abstract][Full Text] [Related]
3. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
4. Targeting aspartate aminotransferase in breast cancer.
Thornburg JM; Nelson KK; Clem BF; Lane AN; Arumugam S; Simmons A; Eaton JW; Telang S; Chesney J
Breast Cancer Res; 2008; 10(5):R84. PubMed ID: 18922152
[TBL] [Abstract][Full Text] [Related]
5. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.
Shajahan-Haq AN; Cook KL; Schwartz-Roberts JL; Eltayeb AE; Demas DM; Warri AM; Facey CO; Hilakivi-Clarke LA; Clarke R
Mol Cancer; 2014 Oct; 13():239. PubMed ID: 25339305
[TBL] [Abstract][Full Text] [Related]
6. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY
Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969
[TBL] [Abstract][Full Text] [Related]
7. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
8. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
9. Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models.
Li Y; Drabsch Y; Pujuguet P; Ren J; van Laar T; Zhang L; van Dam H; Clément-Lacroix P; Ten Dijke P
Breast Cancer Res; 2015 Feb; 17(1):28. PubMed ID: 25849225
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the low inhibitory specificity of oxamate, aminooxyacetate and dichloroacetate on cancer energy metabolism.
Moreno-Sánchez R; Marín-Hernández Á; Del Mazo-Monsalvo I; Saavedra E; Rodríguez-Enríquez S
Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3221-3236. PubMed ID: 27538376
[TBL] [Abstract][Full Text] [Related]
13. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer.
Inao T; Harashima N; Monma H; Okano S; Itakura M; Tanaka T; Tajima Y; Harada M
Breast Cancer Res Treat; 2012 Jul; 134(1):89-100. PubMed ID: 22203435
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
16. Stimulation by aminooxyacetate of fluorescein uptake in rat renal tubules in vitro: role of intracellular alpha-ketoglutarate.
Nikiforov AA
J Pharmacol Exp Ther; 1995 Sep; 274(3):1204-8. PubMed ID: 7562489
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.
Lieberman BP; Ploessl K; Wang L; Qu W; Zha Z; Wise DR; Chodosh LA; Belka G; Thompson CB; Kung HF
J Nucl Med; 2011 Dec; 52(12):1947-55. PubMed ID: 22095958
[TBL] [Abstract][Full Text] [Related]
18. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
19. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc.
Nass SJ; Dickson RB
Clin Cancer Res; 1998 Jul; 4(7):1813-22. PubMed ID: 9676860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
